Taro Pharmaceutical Industries Ltd.

Equities

TARO

IL0010827181

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-04-24 pm EDT 5-day change 1st Jan Change
42.2 USD -0.07% Intraday chart for Taro Pharmaceutical Industries Ltd. -0.09% +1.01%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Taro Pharmaceutical Industries Fiscal Q3 Net Income, Net Sales Rise; Shares Climb After Hours MT
Taro Pharmaceutical Industries Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
HC Wainwright Downgrades Taro Pharmaceutical Industries to Neutral From Buy, $43 Price Target MT
India's Sun Pharma to buy remaining stake in Israeli unit Taro for about $348 mln RE
Taro Pharmaceutical to go Private in Merger Deal With Sun Pharmaceutical MT
Sun Pharmaceutical to Take Taro Private at $43/Share DJ
Sector Update: Health Care Stocks Advance Late Afternoon MT
Sector Update: Health Care Stocks Advance Tuesday Afternoon MT
Sector Update: Health Care MT
Taro Pharmaceutical Committee Agrees in Principle With Sun Pharmaceutical's Revised Acquisition Offer MT
Sun Pharma Raises Offer to Buy Taro Pharmaceutical Industries' US Arm CI
Taro Pharmaceutical Industries Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Sun Pharmaceutical Industries Looking to Fully Acquire Its Israel-Based Unit Taro Pharmaceutical Industries CI
Earnings Flash (TARO) TARO PHARMACEUTICAL INDUSTRIES Posts Q1 Revenue $158.9M, vs. Street Est of $149M MT
Taro Pharmaceutical Industries Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Taro Pharmaceutical's Shareholder Krensavage Says It 'Opposes' Sun Pharmaceutical Industries Takeover Offer MT
Sun Pharmaceutical Industries Limited completed the acquisition of remaining unknown majority stake in Taro Pharmaceutical Industries Ltd.. CI
Taro Pharmaceutical Industries Ltd. Appoints Mr. Oded H. Sarig, Ph. D, to Serve as Director CI
Taro Pharmaceutical Industries Ltd. Announces Resignation of Dov Pekelman from the Board of Directors CI
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday MT
Sector Update: Health Care MT
Taro Pharmaceutical Receives Takeover Offer From Sun Pharmaceutical for $38 Per Share in Cash MT
Taro Pharmaceutical Shares Surge Premarket as Sun Pharma Proposes Buyout DJ
Top Premarket Gainers MT
Sun Pharmaceutical Offers to Acquire Remaining Stake in Taro Pharmaceutical MT
Chart Taro Pharmaceutical Industries Ltd.
More charts
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
42.2 USD
Average target price
43 USD
Spread / Average Target
+1.90%
Consensus